Skip to main content
. Author manuscript; available in PMC: 2017 Aug 23.
Published in final edited form as: Eur Urol. 2016 May 6;70(6):963–970. doi: 10.1016/j.eururo.2016.04.023

Fig. 4.

Fig. 4

Secondary end points: (A) Time to prostate-specific antigen progression (PSA); (B) metastasis-free survival.

CI = confidence interval; NR = not reached.